Reducing treatment volume for spinal metastases using stereotactic body radiation therapy
Official title: A Randomized, Pilot Study on tREatment VOLume De-escalation for SPINal mEtastases SBRT (REVOL-SPINE)
Run by IRCCS Sacro Cuore Don Calabria di Negrar · NCT07538024 · Data updated 2026-11-12
This pilot study will try using MRI-defined tumor volumes instead of standard guideline volumes for SBRT in adults with up to five spinal metastases.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | IRCCS Sacro Cuore Don Calabria di Negrar Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Negrar, Verona) |
| Status | Recruiting |
| Started | November 4, 2025 |
| Main results expected | May 4, 2029 |
| Study ends | May 4, 2029 |
| Registry record updated | April 20, 2026 |
| Trial ID | NCT07538024 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age >18) with up to five metastatic lesions, ECOG 0-1, life expectancy over 12 months, SINS < 7, and a single active lesion per treated vertebra who are candidates for SBRT are eligible.
✕Probably not a fit
Patients with more than five metastases, more than two adjacent vertebrae involved, multiple lesions in the same vertebra, contraindications to MRI, or those treated with palliative intent are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, randomized (1:1), unblinded pilot compares two SBRT planning approaches for vertebral metastases: standard Cox guideline contouring versus MRI-defined pathological lesion volumes. Each vertebral metastasis is randomized and treated in three or five fractions after CT simulation and MRI coregistration; GTV is defined using MRI (and PET if available) with a 2 mm isotropic PTV margin while avoiding the spinal canal. Follow-up includes MRI at 3 and 6 months and then every 6 months up to two years, with routine visits to record adverse events and pain using the NRS. Outcomes focus on local response, toxicity, and pain changes compared to baseline.
Why it matters
Potential benefit: If successful, this approach could reduce radiation exposure to nearby healthy spinal tissues while maintaining local tumor control.
How similar studies have gone: MRI-based target delineation and precise SBRT targeting are established practices, but randomized evidence specifically testing systematic volume de-escalation for spinal metastases is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients affected by spinal metastases eligible for SBRT * All histologies are allowed * Oligometastatic disease (maximum 5 metastases) in every setting (oligopersistent, oligorecurrent and oligoprogressive, according to ESTRO consensus) * Metastases treated with ablative intent * Both symptomatic and asymptomatic vertebral metastases * Spine Instability Neoplastic Score (SINS) score \< 7 \[18\] * Age \> 18 years * Life expectancy \> 12 months * PS ECOG 0-1 * Vertebral pathological lesion on the diagnostic MRI * Single active lesion on the target vertebra * More lesions in different vertebrae can be simultaneously treated * Informed consent to trial participation and personal data treatment Exclusion Criteria: * More than 2 adjoining vertebrae involved * Palliative intent * 2 or more lesions on the target vertebra * Contraindications to MRI * More than 5 metastases
Where it's running
-
IRCCS Sacro Cuore Don Calabria
Negrar, Verona, Italy Recruiting
Study contacts
- Study coordinator: Elvia Malo, Dr.
- Email: elvia.malo@sacrocuore.it
- Phone: +39 0456014854
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Zanzalintinib with a bone-strengthening agent for metastatic clear cell RCC with bone metastases
This phase 2 trial tests zanzalintinib plus a bone-strengthening agent in adults with metastatic clear cell renal cell cancer that has spread to bone and progressed after 1–3 prior therapies, including IO therapy.
-
Assessing bone strength in patients with metastatic cancer using CT scans
This study is testing if special CT scans can help doctors better understand the risk of fractures in patients with bone cancer from breast cancer or lung cancer.
-
Intensive Visual Simulation before exoskeleton gait training in people with hemisensory brain injury
This study tests whether a brief IVS session before exoskeleton-assisted walking helps people with sensory- impaired stroke-related hemiparesis to walk independently.
-
Robotic upper-limb rehab vs standard therapy for adults with tetraplegia
This study tests whether a robotic arm rehabilitation device (PABLO®) plus standard therapy helps people with tetraplegia recover more upper-limb strength than standard rehab alone.
-
Duodenal organoids to study how the gut lining interacts with pathogens
Researchers are using tissue from patients who have part of their duodenum removed to grow living 3D organoids and test how the intestinal epithelium responds to pathogens in the lab.
-
Infectious disease screening for asylum seekers at a reception center
A one-time blood, urine, stool testing and physical exam to test for common infections in asylum seekers who have been in Italy between 2 and 36 months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.